File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of Cisplatin in iodized oil and gelfoam

TitleTreatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of Cisplatin in iodized oil and gelfoam
Authors
Issue Date1993
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/crad
Citation
Clinical Radiology, 1993, v. 47 n. 5, p. 315-320 How to Cite?
AbstractEighty patients with inoperable hepatocellular carcinoma (HCC) were treated by transcatheter arterial chemoembolization using an emulsion of Lipiodol and Cisplatin. In 59 patients, gelfoam embolization was also given. The tumour size ranged from 0.5 cm to 33 cm in maximum diameter with the median diameter being 8 cm. The chemoembolization sessions were repeated every 1 1/2 to 3 months. The number of sessions the patients underwent varied from 1 to 11, with the mean number of sessions being 3.7. The HCC either disappeared completely or decreased in size in 44 patients (55%). In patients having an HCC of 12 cm or less in size, 31 out of 41 (75.6%) who had the addition of gelfoam demonstrated decrease in tumour size, while seven out of 11(63.6%) without the addition of gelfoam demonstrated decrease in tumour size. In patients having an HCC of more than 12 cm in size, only six out of 18 (33.3%) who had the addition of gelfoam demonstrated reduction in tumour size and none of the 10 patients without the addition of gelfoam responded. Thus, HCCs of 12 cm or less in size responded better than larger ones to chemoembolization (P < 0.0001) while the addition of gelfoam enhanced the response (P = 0.039). The 1 year survival rate for the 80 patients was 53% and the 2 years survival rate was 38%. The median survival was 13 months. For patients having an HCC of 12 cm or less in size, the 1 year and 2 year survival rates were 69% and 47% respectively. For patients having a larger tumour, the 1 year survival rate was 24%. For patients in whom there was a decrease in tumour size after chemoembolization, the 1 year and 2 year survival rates were 79% and 60% respectively. For patients in whom there was no response, the 1 year survival rate was 21%. Thus, patients with tumours of 12 cm or less in size survived significantly longer than those having larger tumours (P < 0.0001) while responders survived significantly longer than non-responders (P < 0.0001).
Persistent Identifierhttp://hdl.handle.net/10722/161971
ISSN
2015 Impact Factor: 2.151
2015 SCImago Journal Rankings: 0.864
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNgan, Hen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLai, ECSen_HK
dc.contributor.authorYuen, WKen_HK
dc.contributor.authorTso, WKen_HK
dc.date.accessioned2012-09-05T05:16:23Z-
dc.date.available2012-09-05T05:16:23Z-
dc.date.issued1993en_HK
dc.identifier.citationClinical Radiology, 1993, v. 47 n. 5, p. 315-320en_HK
dc.identifier.issn0009-9260en_HK
dc.identifier.urihttp://hdl.handle.net/10722/161971-
dc.description.abstractEighty patients with inoperable hepatocellular carcinoma (HCC) were treated by transcatheter arterial chemoembolization using an emulsion of Lipiodol and Cisplatin. In 59 patients, gelfoam embolization was also given. The tumour size ranged from 0.5 cm to 33 cm in maximum diameter with the median diameter being 8 cm. The chemoembolization sessions were repeated every 1 1/2 to 3 months. The number of sessions the patients underwent varied from 1 to 11, with the mean number of sessions being 3.7. The HCC either disappeared completely or decreased in size in 44 patients (55%). In patients having an HCC of 12 cm or less in size, 31 out of 41 (75.6%) who had the addition of gelfoam demonstrated decrease in tumour size, while seven out of 11(63.6%) without the addition of gelfoam demonstrated decrease in tumour size. In patients having an HCC of more than 12 cm in size, only six out of 18 (33.3%) who had the addition of gelfoam demonstrated reduction in tumour size and none of the 10 patients without the addition of gelfoam responded. Thus, HCCs of 12 cm or less in size responded better than larger ones to chemoembolization (P < 0.0001) while the addition of gelfoam enhanced the response (P = 0.039). The 1 year survival rate for the 80 patients was 53% and the 2 years survival rate was 38%. The median survival was 13 months. For patients having an HCC of 12 cm or less in size, the 1 year and 2 year survival rates were 69% and 47% respectively. For patients having a larger tumour, the 1 year survival rate was 24%. For patients in whom there was a decrease in tumour size after chemoembolization, the 1 year and 2 year survival rates were 79% and 60% respectively. For patients in whom there was no response, the 1 year survival rate was 21%. Thus, patients with tumours of 12 cm or less in size survived significantly longer than those having larger tumours (P < 0.0001) while responders survived significantly longer than non-responders (P < 0.0001).en_HK
dc.languageengen_US
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/craden_HK
dc.relation.ispartofClinical Radiologyen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Mortality - Therapyen_US
dc.subject.meshCatheterization, Peripheralen_US
dc.subject.meshChemoembolization, Therapeutic - Adverse Effects - Methodsen_US
dc.subject.meshCisplatin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshEmulsionsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGelatin Sponge, Absorbable - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshIodized Oil - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshLiver Neoplasms - Mortality - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.titleTreatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of Cisplatin in iodized oil and gelfoamen_HK
dc.typeArticleen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0009-9260(05)81446-1en_HK
dc.identifier.pmid8389682-
dc.identifier.scopuseid_2-s2.0-0027200252en_HK
dc.identifier.volume47en_HK
dc.identifier.issue5en_HK
dc.identifier.spage315en_HK
dc.identifier.epage320en_HK
dc.identifier.isiWOS:A1993LA60700004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridNgan, H=7102173824en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLai, ECS=55025749000en_HK
dc.identifier.scopusauthoridYuen, WK=7102761292en_HK
dc.identifier.scopusauthoridTso, WK=7006905486en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats